Het laatste nieuws

Hier vindt u onze laatste persberichten. Blijf op de hoogte van het laatste nieuws en van de evenementen waar Curium aanwezig is.

26th mei 2023

Curium receives positive CHMP opinion of PYLCLARI® for primary staging of patients with high-risk PCa prior to initial curative therapy and to localize recurrence of PCa in patients with a suspected recurrence based on increasing serum Prostate-Specific Antigen (PSA) levels after primary treatment with curative intent

23rd mei 2023

Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T

2nd mei 2023

Curasight and Curium announce global partnership for uTRACE® in prostate cancer

14th maart 2023

Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial

2nd maart 2023

Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO

27th januari 2023

Curium is attending these global congresses in 2023

21st december 2022

Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99

24th november 2022

Curium’s Customers to benefit from Mo-99 Production restart

22nd november 2022

Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.

9th november 2022

Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients

18th augustus 2022

NRG and Curium Sign Multi-Year Isotope Production Contract

27th juni 2022

Curium Announces The Submission Of Its Marketing Authorization Application For [¹⁸F]-DCFPyL To The European Medicines Agency

12th mei 2022

Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

3rd mei 2022

Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients

19th april 2022

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

5th april 2022

Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.

25th januari 2022

Curium to become major player in the supply on non carrier added Lu-177

15th december 2021

Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer

27th oktober 2021

Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

24th augustus 2021

Filteren op

Het laatste nieuws

Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T

Curasight and Curium announce global partnership for uTRACE® in prostate cancer

Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial

Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO

Curium is attending these global congresses in 2023

Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99

Curium’s Customers to benefit from Mo-99 Production restart

Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.

Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients

NRG and Curium Sign Multi-Year Isotope Production Contract

Curium Announces The Submission Of Its Marketing Authorization Application For [¹⁸F]-DCFPyL To The European Medicines Agency

Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.

Curium to become major player in the supply on non carrier added Lu-177

Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer

Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T

Filteren op

Het laatste nieuws

Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T

Curasight and Curium announce global partnership for uTRACE® in prostate cancer

Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial

Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO

Curium is attending these global congresses in 2023

Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99

Curium’s Customers to benefit from Mo-99 Production restart

Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.

Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients

NRG and Curium Sign Multi-Year Isotope Production Contract

Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency

Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.

Curium to become major player in the supply on non carrier added Lu-177

Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer

Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T

Curium Announces The Submission Of Its Marketing Authorization Application For [¹⁸F]-DCFPyL To The European Medicines Agency